https://www.openbell.ai/ 2026-10-19T10:43:02.351Z hourly 1.0 https://www.openbell.ai/support 2026-10-19T10:43:02.351Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-19T10:43:02.351Z monthly 0.5 https://www.openbell.ai/terms 2026-10-19T10:43:02.351Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-19T10:43:02.351Z hourly 0.8 https://www.openbell.ai/news/SLGN:1792406533351 2026-10-19T10:42:13.351Z daily 0.9 https://cdn.brandfetch.io/SLGN/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Silgan Nears $3.4 Billion Purchase of Trivium Packaging' - Bloomberg Silgan Holdings is nearing a $3.4 billion acquisition of Trivium Packaging, which is expected to enhance its product offerings in the packaging sector. This strategic move aims to strengthen Silgan's market position and expand its capabilities. The deal reflects Silgan's ongoing efforts to grow through acquisitions in the competitive packaging industry. https://www.openbell.ai/news/UBER:1792406459609 2026-10-19T10:40:59.609Z daily 0.9 https://cdn.brandfetch.io/UBER/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Uber Wins Bid to Dismiss £250 Million Black Cab Driver Suit' - Bloomberg Uber has successfully dismissed a £250 million lawsuit filed by black cab drivers in the UK. The lawsuit alleged that Uber's operations were unfairly impacting the traditional taxi industry. This legal victory may have positive implications for Uber's financial standing and market position in the UK. https://www.openbell.ai/news/DOW:1792406347070 2026-10-19T10:39:07.070Z daily 0.9 https://cdn.brandfetch.io/DOW/w/400/h/400?c=1idopYfmtR7ZKg8QMud B of A Securities Upgrades Dow to Neutral, Raises Price Target to $31 B of A Securities has upgraded Dow (NYSE: DOW) from Underperform to Neutral, as announced by analyst Matthew DeYoe. Additionally, the price target for Dow's stock has been increased from $29 to $31. https://www.openbell.ai/news/KKR:1792406241312 2026-10-19T10:37:21.312Z daily 0.9 https://cdn.brandfetch.io/KKR/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'KKR to Sell Railcar-Leasing Company Infinity to Ares for $2.9 Billion' - WSJ KKR is set to sell its railcar-leasing company, Infinity, to Ares for $2.9 billion. This transaction marks a significant move in the railcar leasing market and reflects KKR's strategic focus on optimizing its portfolio. The sale is expected to impact KKR's financial standing, although specific details on revenue or profit from the sale were not disclosed. https://www.openbell.ai/news/LCII:1792406232387 2026-10-19T10:37:12.387Z daily 0.9 https://cdn.brandfetch.io/LCII/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Downgrades LCI Industries to Hold, Lowers Price Target to $80 Stifel analyst Nathan Jones has downgraded LCI Industries (NYSE: LCII) from a 'Buy' to 'Hold' rating. Additionally, the price target for the stock has been reduced from $130 to $80. https://www.openbell.ai/news/INFY:1792406132372 2026-10-19T10:35:32.372Z daily 0.9 https://cdn.brandfetch.io/INFY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Infosys Expands Collaboration With Truist To Support Bank's Continued Build-Out Of Its AI-First Global Capability Center In Hyderabad Infosys (NSE: INFY, BSE: INFY, NYSE: INFY) has expanded its collaboration with Truist, a major US financial services firm, to support the development of an AI-first Global Capability Center in Hyderabad. This partnership aims to consolidate multiple supplier relationships into a unified operating model, leveraging Infosys's expertise in financial services and AI. The initiative will also see the onboarding of over 1,000 new employees, marking a significant milestone in the growth of the center. https://www.openbell.ai/news/RXRX:1792406071858 2026-10-19T10:34:31.858Z daily 0.9 https://cdn.brandfetch.io/RXRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target Needham analyst Gil Blum has reiterated a Buy rating on Recursion Pharmaceuticals (NASDAQ: RXRX) and has maintained a price target of $8 for the stock. https://www.openbell.ai/news/AOS:1792406042790 2026-10-19T10:34:02.790Z daily 0.9 https://cdn.brandfetch.io/AOS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Stifel Downgrades A.O. Smith to Hold, Lowers Price Target to $59 Stifel analyst Nathan Jones has downgraded A.O. Smith (NYSE: AOS) from a Buy rating to Hold. Additionally, the price target for the stock has been reduced from $70 to $59. https://www.openbell.ai/news/USAS:1792406021123 2026-10-19T10:33:41.123Z daily 0.9 https://cdn.brandfetch.io/USAS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Americas Gold And Silver Reports Consolidated Silver Production Of 800,458 Ounces For Q3 2026; Sells 860,850 Ounces Of Silver In Q3 Americas Gold and Silver Corporation reported a record consolidated silver production of 800,458 ounces for Q3 2026 and sold 860,850 ounces of silver during the same period. Additionally, the company produced 964,551 pounds of lead (with sales of 1,417,512 pounds), 918,456 pounds of copper (sales of 928,967 pounds), and 101,011 pounds of antimony (sales of 121,691 pounds). https://www.openbell.ai/news/SLGL:1792405983162 2026-10-19T10:33:03.162Z daily 0.9 https://cdn.brandfetch.io/SLGL/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Sol-Gel Technologies, Maintains $110 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Sol-Gel Technologies (NASDAQ: SLGL) and maintained a price target of $110. This endorsement reflects the firm's confidence in the company's potential for growth. https://www.openbell.ai/news/CBZ:1792405971530 2026-10-19T10:32:51.530Z daily 0.9 https://cdn.brandfetch.io/CBZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud CBIZ Q3 Adj. EPS $1.21 Misses $1.29 Estimate, Sales $702.240M Miss $720.549M Estimate CBIZ (NYSE: CBZ) reported Q3 adjusted earnings per share of $1.21, falling short of the $1.29 estimate by 6.2%. Despite this miss, the earnings reflect a 19.8% increase from $1.01 per share in the same quarter last year. The company's sales totaled $702.240 million, also missing the $720.549 million estimate by 2.54%, but marking a 1.21% increase from $693.818 million in the prior year. https://www.openbell.ai/news/ZNTL:1792405769907 2026-10-19T10:29:29.907Z daily 0.9 https://cdn.brandfetch.io/ZNTL/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado has reiterated a Buy rating on Zentalis Pharmaceuticals (NASDAQ: ZNTL) and maintained a price target of $10 for the stock. https://www.openbell.ai/news/DIS:1792405687317 2026-10-19T10:28:07.317Z daily 0.9 https://cdn.brandfetch.io/DIS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reported October 16, 'CFP reaches 'handshake agreement' with ESPN to air 24-team playoff, sources say' - ESPN ESPN has reached a 'handshake agreement' to air a 24-team College Football Playoff (CFP), according to sources. This strategic move is expected to enhance ESPN's sports programming and could impact viewership and advertising revenue. The agreement reflects ESPN's ongoing commitment to college sports and may influence the competitive landscape in sports broadcasting. https://www.openbell.ai/news/ELVN:1792405682963 2026-10-19T10:28:02.963Z daily 0.9 https://cdn.brandfetch.io/ELVN/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73 HC Wainwright & Co. analyst Robert Burns has maintained a 'Buy' rating on Enliven Therapeutics (NASDAQ: ELVN) and increased the price target from $65 to $73. This adjustment reflects a positive outlook for the company's performance in the market. https://www.openbell.ai/news/HRMY:1792405579548 2026-10-19T10:26:19.548Z daily 0.9 https://cdn.brandfetch.io/HRMY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences Holdings (NASDAQ: HRMY) and maintained a price target of $50 for the stock. https://www.openbell.ai/news/MSFT:1792405484050 2026-10-19T10:24:44.050Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/New-York--Ny--Usa---July-5--2022-Microso.jpg?width=250&height=187 AI Boom Hits a Power Wall: Microsoft Walks Away From Nscale's UK Data Center Deal Microsoft Corp. has withdrawn from a planned data center deal with Nscale in Loughton, Essex, due to power supply uncertainties, with grid officials indicating that power may not be available until the 2030s. The project was intended to utilize the facility's 50-megawatt capacity to support Microsoft's AI investments, including housing approximately 23,000 NVIDIA GB300 chips. Despite this setback, Nscale remains committed to the project and is exploring alternative power sources, while also preparing for a potential IPO to raise up to $3 billion amid concerns over funding for AI infrastructure expansion. https://www.openbell.ai/news/RIG:1792405484028 2026-10-19T10:24:44.028Z daily 0.9 https://cdn.brandfetch.io/RIG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Transocean Awarded Two U.S. Gulf Contracts For Its Ultra-Deepwater Drillships Totaling ~$550M In Firm Backlog Transocean has secured two contracts for its ultra-deepwater drillships in the U.S. Gulf, totaling approximately $550 million in firm backlog. The Deepwater Proteus will undertake a ten-well contract estimated at $325 million, starting in Q1 2027, while the Deepwater Conqueror has a five-well contract worth about $225 million, set to begin in Q3 2027. Both contracts will continue the rigs' existing operations in their respective regions. https://www.openbell.ai/news/UEC:1792405388528 2026-10-19T10:23:08.528Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Nvidia--Nokia--Bloom-Energy--Visa-And-Ca.jpg?width=250&height=187 Top 3 Energy Stocks That May Explode In October The article highlights three energy stocks that are currently considered oversold, presenting potential buying opportunities. NexGen Energy Ltd (NYSE:NXE) has an RSI of 28.7 and closed at $8.37 after a recent 11% decline. Uranium Energy Corp (NYSE:UEC) has an RSI of 25.3, with shares dropping 22% recently to close at $7.91. Centrus Energy Corp (NYSE:LEU) has an RSI of 26.5, and its stock fell 18% over five days to close at $114.94. https://www.openbell.ai/news/VEON:1792405302107 2026-10-19T10:21:42.107Z daily 0.9 https://cdn.brandfetch.io/VEON/w/400/h/400?c=1idopYfmtR7ZKg8QMud VEON To Acquire 100% Of Uzbekistan Mobile Operator Rubicon Wireless, Trading Under 'Perfectum' Brand, For $207M VEON has announced its acquisition of 100% of Uzbekistan mobile operator Rubicon Wireless, trading under the 'Perfectum' brand, for approximately $207 million, which includes $93 million of Perfectum's outstanding financial debt. This acquisition will enhance VEON's operations in Uzbekistan by expanding its spectrum portfolio and improving network capabilities, particularly for 4G/LTE and future 5G services. The deal is expected to increase Beeline Uzbekistan's spectrum holdings by about 50% and generate synergies through integration with existing networks. https://www.openbell.ai/news/CBIO:1792405192637 2026-10-19T10:19:52.637Z daily 0.9 https://cdn.brandfetch.io/CBIO/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating on Crescent Biopharma (NASDAQ: CBIO) and maintained a price target of $36 for the stock. https://www.openbell.ai/news/QNT:1792405099230 2026-10-19T10:18:19.230Z daily 0.9 https://cdn.brandfetch.io/QNT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Quantinuum CEO Claims Error-Correction Code Achieved 99.9995% Fidelity; Improvement Unlocks New Commercial Use Cases - WSJ Interview openbell Financial News https://www.openbell.ai/news/ADAG:1792405060753 2026-10-19T10:17:40.753Z daily 0.9 https://cdn.brandfetch.io/ADAG/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $7 Price Target HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on Adagene (NASDAQ: ADAG) and maintained a price target of $7 for the stock. No additional financial figures or strategic changes were mentioned in the article. https://www.openbell.ai/news/HDRN:1792404946938 2026-10-19T10:15:46.938Z daily 0.9 https://cdn.brandfetch.io/HDRN/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Initiates Coverage On Hadron Energy with Buy Rating, Announces Price Target of $4.5 HC Wainwright & Co. has initiated coverage on Hadron Energy (NASDAQ: HDRN) with a Buy rating. The firm has set a price target of $4.5 for the stock. https://www.openbell.ai/news/LYV:1792404836357 2026-10-19T10:13:56.357Z daily 0.9 https://cdn.brandfetch.io/LYV/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on Live Nation Entertainment, Maintains $215 Price Target BTIG analyst Tyler DiMatteo has reiterated a Buy rating on Live Nation Entertainment (NYSE: LYV) and maintained a price target of $215 for the stock. This endorsement reflects confidence in the company's performance and market position. https://www.openbell.ai/news/VEON:1792404808733 2026-10-19T10:13:28.733Z daily 0.9 https://cdn.brandfetch.io/VEON/w/400/h/400?c=1idopYfmtR7ZKg8QMud VEON Claims 11M+ Unique Customers Have Connected To Direct-To-Device Service At Least Once In Locations Where There's No Mobile Service VEON has reported that over 11 million unique customers have connected to its Starlink Mobile service, which allows users to access satellite-ready apps and communicate via SMS on LTE-compatible phones in areas without mobile service. The service has been launched in Ukraine, Kazakhstan, and Bangladesh, with Kyivstar, Beeline, and Banglalink respectively, marking significant advancements in connectivity for underserved markets. The initiative aims to provide reliable communication in challenging environments, enhancing access to education and safety during disasters. https://www.openbell.ai/news/AVGO:1792404487077 2026-10-19T10:08:07.077Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/New-York-City--New-York---August-5-2025-.jpg?width=250&height=187 What's Going On With Broadcom Stock Monday? Broadcom Inc. (NASDAQ: AVGO) stock rose nearly 3% in premarket trading, reaching $337.50, as technology stocks gained traction amid improving market sentiment. Despite this uptick, the stock remains below key moving averages, indicating potential short-term recovery rather than a sustained rally. Analysts maintain a consensus Buy rating with an average price target of $518.72, reflecting confidence in Broadcom's growth, particularly in its enterprise AI initiatives through VMware Private AI Cloud, which is expected to grow significantly in the coming years. https://www.openbell.ai/news/GILD:1792404483313 2026-10-19T10:08:03.313Z daily 0.9 https://cdn.brandfetch.io/GILD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gilead Announces Emvistegrast 200 Mg Met Primary Endpoint In Phase 2 Swift Dose-Ranging Study; Demonstrated Significant Differences Across Multiple Secondary Measures Of Disease Activity Based On Nominal P-Values; Plans To Initiate Phase 3 Emvistegrast Monotherapy Study In 2027 Gilead Sciences announced that its drug Emvistegrast met its primary endpoint in a Phase 2 swift dose-ranging study, showing significant differences across multiple secondary measures of disease activity based on nominal p-values. The company plans to initiate a Phase 3 study for Emvistegrast as monotherapy in 2027. https://www.openbell.ai/news/ACAD:1792404472694 2026-10-19T10:07:52.694Z daily 0.9 https://cdn.brandfetch.io/ACAD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target Needham analyst Ami Fadia has reiterated a Buy rating on Acadia Pharmaceuticals (NASDAQ: ACAD) and maintained a price target of $35. This endorsement reflects confidence in the company's performance and potential in the market. https://www.openbell.ai/news/IDYA:1792404458384 2026-10-19T10:07:38.384Z daily 0.9 https://cdn.brandfetch.io/IDYA/w/400/h/400?c=1idopYfmtR7ZKg8QMud IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress IDEAYA Biosciences, Inc. (NASDAQ: IDYA) will present updated clinical data on its melanoma drug darovasertib at the ESMO Congress 2026 from October 23-27 in Madrid, Spain. The presentation will include Phase 2 expansion data from the OptimUM-01 study for HLA-A*02:01-positive metastatic uveal melanoma patients, subgroup analyses from the OptimUM-02 trial for HLA-A*02:01-negative patients, and follow-up data from the OptimUM-09 trial for primary uveal melanoma. https://www.openbell.ai/news/PERF:1792404359426 2026-10-19T10:05:59.426Z daily 0.9 https://cdn.brandfetch.io/PERF/w/400/h/400?c=1idopYfmtR7ZKg8QMud Perfect Corp Moves Closer To Going Private After Shareholders Back Merger Perfect Corp. (NYSE: PERF) shareholders have approved the Merger Agreement with ProjectNY, a Cayman Islands company controlled by Ms. Alice H. Chang, with approximately 99.99% of votes in favor. About 68.6% of the total ordinary shares were represented at the extraordinary general meeting. The merger will result in Perfect Corp. becoming a privately held company, pending the satisfaction of conditions outlined in the Merger Agreement. https://www.openbell.ai/news/BDSX:1792404234265 2026-10-19T10:03:54.265Z daily 0.9 https://cdn.brandfetch.io/BDSX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Biodesix Adds AI-Powered Imaging Test To Expand Lung Cancer Risk Screening Biodesix, Inc. (NASDAQ: BDSX) has announced the addition of an AI-powered imaging test to its Lung Diagnostics strategy, marking a significant expansion into multimodal diagnostics that combines blood-based and imaging biomarkers. The first product, developed in collaboration with Vanderbilt University, focuses on lung nodule risk assessment and is set to complement the existing Nodify Lung® portfolio. Initial data will be presented at RSNA on December 3, 2026, with commercial availability expected in 2028, positioning Biodesix to enhance its lung cancer risk assessment capabilities. https://www.openbell.ai/news/BLTE:1792404135271 2026-10-19T10:02:15.271Z daily 0.9 https://cdn.brandfetch.io/BLTE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19 Belite Bio, Inc. has received approval from Nasdaq to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading under the ticker symbol 'BLTE' will begin on October 19, 2026. The company focuses on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs. https://www.openbell.ai/news/TSLA:1792404007754 2026-10-19T10:00:07.754Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/SpaceX-starships-in-launch-position-at-t.jpg?width=250&height=187 Elon Musk Challenges Jeff Bezos' Blue Origin and Other SpaceX Rivals, Says They Still Can’t Catch Starship — ‘Even Their Future Plans Are Behind’ Space Exploration Technologies Corp. (NASDAQ: SPCX) is set to report its third-quarter 2026 earnings, with analysts expecting revenue of $12.94 billion and an EPS of $0.16 per share. CEO Elon Musk has expressed confidence in SpaceX's Starship, claiming it is ahead of competitors like Blue Origin and Rocket Lab, the latter of which recently delayed its Neutron rocket launch to 2027, impacting its valuation. Additionally, SpaceX shares rose 1.42% to $148.10 during overnight trading. https://www.openbell.ai/news/BCAX:1792403819369 2026-10-19T09:56:59.369Z daily 0.9 https://cdn.brandfetch.io/BCAX/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target BTIG analyst Jeet Mukherjee has reiterated a Buy rating on Bicara Therapeutics (NASDAQ: BCAX) and maintained a price target of $39 for the stock. No additional financial figures or strategic changes were mentioned in the article. https://www.openbell.ai/news/INTC:1792403757802 2026-10-19T09:55:57.802Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/New-York-City--New-York---September-18-2.jpg?width=250&height=187 What's Going On With Intel Stock Monday? Intel Corp. (NASDAQ: INTC) stock increased approximately 4% in premarket trading on Monday, continuing a 140% rally in 2026, driven by a broader technology rally ahead of its earnings report on October 29. Analysts anticipate earnings of 39 cents per share and revenue of $16.44 billion, up from 23 cents and $13.65 billion respectively, compared to the previous year. Additionally, Intel announced day-0 support for Meta Platforms Inc.'s AI model on its Xeon processors, emphasizing its commitment to enterprise AI infrastructure. The company is also set to showcase its AI technologies at the Web Summit 2026 in Lisbon, Portugal, from November 9-12. https://www.openbell.ai/news/KKR:1792403738455 2026-10-19T09:55:38.455Z daily 0.9 https://cdn.brandfetch.io/KKR/w/400/h/400?c=1idopYfmtR7ZKg8QMud European Commission Says KKR May Have Provided Incorrect Or Misleading Information On 2024 Telecom Italia Fixed-Line Network Deal; EC Has Sent The Company A Statement Of Objections The European Commission has issued a Statement of Objections to KKR, indicating that the firm may have provided incorrect or misleading information regarding its 2024 deal for Telecom Italia's fixed-line network. This development raises concerns about KKR's compliance with regulatory standards in the telecommunications sector. https://www.openbell.ai/news/ORKA:1792403646393 2026-10-19T09:54:06.393Z daily 0.9 https://cdn.brandfetch.io/ORKA/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target BTIG analyst Julian Harrison has reiterated a Buy rating on Oruka Therapeutics (NASDAQ: ORKA) and has maintained a price target of $151 for the stock. This endorsement suggests confidence in the company's future performance. https://www.openbell.ai/news/TAK:1792403629670 2026-10-19T09:53:49.670Z daily 0.9 https://cdn.brandfetch.io/TAK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Takeda Announces New Data From VERDICT Showing That Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Resulted In Significantly Longer Time To First Ulcerative Colitis-Related Complication, Reducing UC Complication Risk By Nearly 70% Takeda (TAK) announced new data from the VERDICT clinical trial, indicating that intravenous ENTYVIO (vedolizumab) treatment aimed at achieving corticosteroid-free disease clearance significantly prolongs the time to the first ulcerative colitis (UC)-related complication, reducing the risk by nearly 70% (hazard ratio 0.33, P=0.0014). The study showed that about 60% of patients reached their assigned treatment targets within 48 weeks, with a notable safety profile consistent with previous data. These findings were presented at the United European Gastroenterology Week 2026 and suggest that deeper remission may alter the disease course for patients with moderate to severe UC. https://www.openbell.ai/news/ACN:1792403570442 2026-10-19T09:52:50.442Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Warsaw--Poland---May-2020-Accenture-Comp.jpg?width=250&height=187 Accenture Reportedly Weighs $1.5 Billion Sale of Greater China Business After Attracting Unsolicited Interest Over Past Year Accenture PLC is considering a potential sale of its Greater China operations, which could be valued at up to $1.5 billion, following unsolicited interest over the past year. The company has engaged JPMorgan Chase & Co. to conduct a strategic review of the business, with the possibility of retaining a significant minority stake. In its fiscal fourth quarter, Accenture's Asia Pacific region generated $2.67 billion in revenue, contributing to a total of $18.7 billion, reflecting a 3% increase in U.S. dollars. Accenture's stock closed at $229.68, having fallen 14.39% year-to-date. https://www.openbell.ai/news/BXP:1792403243227 2026-10-19T09:47:23.227Z daily 0.9 https://cdn.brandfetch.io/BXP/w/400/h/400?c=1idopYfmtR7ZKg8QMud Piper Sandler Downgrades BXP to Neutral, Lowers Price Target to $64 Piper Sandler analyst Alexander Goldfarb has downgraded BXP (NYSE: BXP) from Overweight to Neutral. The price target for the stock has been reduced from $72 to $64. https://www.openbell.ai/news/SPCX:1792402831780 2026-10-19T09:40:31.780Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Elon-Musk-is-the-founder--CEO--and-Chief.jpg?width=250&height=187 Elon Musk Says He'll Give Away SPCX Stock to American Kids Through Trump Accounts: 'This Will Be the First of Many' Elon Musk, CEO of SpaceX (NASDAQ: SPCX), announced plans to give one share of SpaceX stock to every child in the U.S. next year, stating this will be the 'first of many' such initiatives. As of June 30, Musk holds a 48.4% stake in SpaceX, comprising over 4.8 billion shares. The announcement coincides with President Trump's promotion of tax-advantaged 'Trump accounts' for children, which have seen significant contributions, including a previous donation of one share of SpaceX by SpaceX President Gwynne Shotwell for over two million children. Following the news, SPCX shares rose 0.93% to $147.39 in pre-market trading. https://www.openbell.ai/news/NVDA:1792401965213 2026-10-19T09:26:05.213Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Los-Angeles---Jan-8-Mark-Cuban-At-The-Sp.jpg?width=250&height=187 Mark Cuban Says US Manufacturing Can Come Back Home From China With One Big Catch: ‘Our Robots and AI vs Their Robots and AI’ Mark Cuban stated that U.S. manufacturing could return from China if the country advances in robotics and artificial intelligence. He emphasized the need for the U.S. to stay ahead in AI to compete effectively, referencing his company, Cost Plus Drugs, which faces challenges due to fees when considering domestic production. Additionally, Nvidia holds a 34% share of China's AI accelerator market, while Huawei has captured 28%, indicating increasing competition in the sector. https://www.openbell.ai/news/SPY:1792399970455 2026-10-19T08:52:50.455Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Wall-Street-in-red.jpg?width=250&height=187 Michael Burry Warns Stocks Could Face 15-20 Years of Poor Real Returns: ‘Speculation Has Overrun Investing’ Investor Michael Burry warns that stock indices are overstretched and predicts a potential 15-20 year period of low or negative real returns based on historical market data and inflation metrics. He highlights that the S&P 500 reached a record high on October 6 without significant trading volume, indicating excessive speculation in the market. Burry draws parallels to past market cycles, citing declines in inflation-adjusted returns during previous bear markets, including a 53% drop from 1966 to 1982. As of now, the S&P 500 has advanced 11.89% year-to-date, but recent trading shows declines for major ETFs, with SPY down 1.11% and QQQ down 2.50%. https://www.openbell.ai/news/VFS:1792399583466 2026-10-19T08:46:23.466Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/The-Real-Villains-No-Longer-Hide.jpg?width=250&height=187 Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket XCF Global Inc (NASDAQ: SAFX) shares increased by approximately 64.9% to $0.23 in pre-market trading following the completion of its business combination with Southern Energy Renewables and DevvStream. The company also updated its financial outlook, projecting net revenue of $120 to $130 million and EBITDA of $70 to $75 million for 2025. https://www.openbell.ai/news/LLY:1792399441181 2026-10-19T08:44:01.181Z daily 0.9 https://cdn.brandfetch.io/LLY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Eli Lilly’s Omvoh Shows 1-Year Phase 3 Results for Kids with Ulcerative Colitis Eli Lilly announced positive one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab) in children aged 6 to 17 with moderately to severely active ulcerative colitis. The study showed that 81% of patients achieved a clinical response at Week 12, with 50% of responders reaching clinical remission by Week 52. Omvoh, already approved for adults, is being evaluated for pediatric use, and if approved, would be the first IL-23p19 inhibitor indicated for this age group. The safety profile in children was consistent with that observed in adults, with no new safety signals identified. https://www.openbell.ai/news/DLR:1792397798094 2026-10-19T08:16:38.094Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Afternoon-sun-shines-on-a-Digital-Realty.jpg?width=250&height=187 Hunterbrook Report: Digital Realty’s $3 Billion Georgia Data Center Hits Toxic Roadblock After White Phosphorus Found At Former Army Dump Digital Realty Trust Inc. (NYSE: DLR) has encountered a significant setback in its plans to construct a $3 billion data center on a $120 million parcel of land in Georgia, previously used as a military dump. Construction was halted after crews discovered combustible white phosphorus, leading to the involvement of local police and a bomb squad. The company plans to invest over $100 million in site remediation, despite acknowledging the site has numerous environmental hazards. As of now, DLR's stock is up 1.16% over the past year, closing at $175.97. https://www.openbell.ai/news/ABBV:1792397135825 2026-10-19T08:05:35.825Z daily 0.9 https://cdn.brandfetch.io/ABBV/w/400/h/400?c=1idopYfmtR7ZKg8QMud AbbVie’s Dual-Target Drug Shows Phase 2 Results for Hard-to-Treat Crohn’s Disease AbbVie announced promising Phase 2 results for its investigational drug ABBV-466, a dual-target therapy for Crohn's disease, showing endoscopic remission rates of 30.2% at Week 12 and 40.5% at Week 24, compared to 21.3% and 22.4% for monotherapies, respectively. The TARGET-CD study involved 300 patients, with 75% having previously failed advanced therapies. Serious adverse event rates for ABBV-466 were comparable to those of existing therapies, indicating a favorable safety profile. The findings will be presented at the 2026 UEGW Congress in Barcelona from October 17-20. https://www.openbell.ai/news/AMD:1792394500794 2026-10-19T07:21:40.794Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/19/Market-sentiment---Fear-and-Greed.jpg?width=250&height=187 Nasdaq Tumbles Over 2%, Records Weekly Loss: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme Fear’ Zone The Nasdaq Composite fell over 2% on Friday, marking its worst weekly performance since June, with a total decline of more than 4% for the week. The S&P 500 also dropped about 2%, while the Dow Jones gained 0.7%. The CNN Money Fear and Greed index indicated a shift to the 'Extreme Fear' zone, with a reading of 18, down from 30. Chipmakers experienced significant losses, particularly the VanEck Semiconductor ETF, which tumbled 3% amid declines in major companies like Micron Technology and AMD. https://www.openbell.ai/news/ESLT:1792394166416 2026-10-19T07:16:06.416Z daily 0.9 https://cdn.brandfetch.io/ESLT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Elbit Secures $235M European Order For Precision-Guided EXTRA-MR Rockets With Ranges Up To 80 Km And Compatible PULS Rocket Artillery Systems openbell Financial News https://www.openbell.ai/news/EVAX:1792394129760 2026-10-19T07:15:29.760Z daily 0.9 https://cdn.brandfetch.io/EVAX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Evaxion’s EVX-01 Phase 2 Trial Shows 92% Of Melanoma Patients Still Responding At Two Years With No Relapses, And All Responses Maintained At Three Years Without Progression openbell Financial News